drug · protein

TRULICITY

updated 3mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 4 investigational indications.

targets

Glucagon-like peptide 1 receptor

all catalysts(0)

nothing on the calendar yet

Trials studying TRULICITY

phase3A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetesnot yet recruitingn=170
phase3A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)recruitingn=55
phase1A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitusactive not recruitingn=20
phase3A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellituscompletedn=632
phase3A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metforminactive not recruitingn=600
phase3A Phase 3 Study of HS-20094 in Patients With T2DMnot yet recruitingn=546
phase3A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetescompletedn=13,299
phase2A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metforminrecruitingn=216

more trials →

News(0)

no news has mentioned this drug yet

brand

TRULICITY

trade names

Dulaglutide component of trulicity, Trulicity

generic

DULAGLUTIDE

MOA

12.1 Mechanism of Action TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.

indication

1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. Limitations of Use: Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in these patients ( 1 , 5.2 ). Not for treatment of type 1 diabetes mellitus ( 1 ). Not recommended in patients with severe gastrointestinal disease, including severe gastroparesis ( 1 , 5.6 ). Limitations of Use TRULICITY: Has not been studied in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . Consider other antidiabetic therapies in patients with a history of pancreatitis. Should not be used in patients with type 1 diabetes mellitus. Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis and is therefore not recommended in these patients [see Warnings and Precautions ( 5.6 )] .

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 31m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

TRULICITY

updated 3mo ago

by $LLY ELI LILLY & Co🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 4 investigational indications.

targets

Glucagon-like peptide 1 receptor

all catalysts(0)

nothing on the calendar yet

Trials studying TRULICITY

phase3A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetesnot yet recruitingn=170
phase3A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)recruitingn=55
phase1A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitusactive not recruitingn=20
phase3A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellituscompletedn=632
phase3A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metforminactive not recruitingn=600
phase3A Phase 3 Study of HS-20094 in Patients With T2DMnot yet recruitingn=546
phase3A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetescompletedn=13,299
phase2A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metforminrecruitingn=216

more trials →

News(0)

no news has mentioned this drug yet

brand

TRULICITY

trade names

Dulaglutide component of trulicity, Trulicity

generic

DULAGLUTIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 31m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

TRULICITY

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRULICITY

News(0)

Report a data issue

comments(0)

TRULICITY

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying TRULICITY

News(0)

Report a data issue

comments(0)